Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
J Clin Invest. 2020 Dec 1;130(12):6409-6416. doi: 10.1172/JCI141772.
J Clin Invest. 2020.
PMID: 32809969
Free PMC article.
Clinical Trial.